If you\u2019ve dealt with a stubborn shoulder, back, or joint problem, you\u2019ve probably already been through the standard playbook. Over-the-counter pain relievers. A stretch of physical therapy. Maybe a corticosteroid shot. For a lot of patients, that helps for a while, and then it doesn\u2019t, or it comes with tradeoffs nobody\u2019s thrilled about. That\u2019s a big part of why regenerative medicine keeps growing as a field, and why we\u2019ve added a new option here at Nivens Spine Medicine: Regenerative Protein Array (RPA) and MUSE-Infused RPA.<\/p>\n
Regenerative medicine gets talked about like it appeared last year, but the underlying idea, helping the body heal itself, goes back a lot further than that. It\u2019s the product of decades of tissue engineering and surgical advances building on each other. RPA is just the latest version of that idea: using biologic material to support the body\u2019s repair process instead of replacing tissue outright.<\/p>\n
NSAIDs are easy to get and usually tolerated fine, but long-term use isn\u2019t free of risk, and they don\u2019t touch the underlying problem. Physical therapy is genuinely one of the better long-term tools for pain and function, though sticking with it is hard when the program itself is uncomfortable or eats up your schedule. Corticosteroid shots can knock down pain and swelling quickly, but a lot of patients notice each one works a little less than the last. None of that makes these options bad, they\u2019re still a real part of a lot of care plans, but it explains some of the interest in alternatives.<\/p>\n
Dr. Nivens has been following regenerative medicine for about a decade, and he\u2019s the first to say he didn\u2019t get behind it right away. \u201cInitially there was a lot of misinformation out there, but also not a lot of information,\u201d he says of when traditional stem cell products first showed up. \u201cI never felt comfortable about getting behind this product, mainly because there was not a lot of research. People were just injecting it into folks and hoping that it would do what they would hope it would do.\u201d Traditional stem cell therapy also comes with a real tradeoff: patients receive live cellular material and DNA from a donor, and that\u2019s been tied to rejection issues and, in some cases, unwanted tissue growth.<\/p>\n